Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04796545
Other study ID # SING IMT PMCF
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 13, 2022
Est. completion date December 2028

Study information

Verified date July 2023
Source VisionCare, Inc.
Contact Anne Roller, PhD
Phone + 33 (0)3 88 30 88 11
Email clinicals@medevise-consulting.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to demonstrate the safety and effectiveness of the SING IMT (Smaller Incision New Generation Implantable Miniature Telescope) 3X implant in improving vision in patients with central vision impairment associated with end-stage Age-related Macular Degeneration (AMD). Eligible patients will be implanted with the SING IMT device and will be followed-up for a period of 12-months with post-operative ophthalmic exams and low-vision rehabilitation sessions.


Description:

This is an interventional, prospective, multicenter, open label, single group assignment Post-Market Clinical Follow-up (PMCF) study in men and women >=55 years with central vision impairment associated with end-stage AMD. Following completion of informed consent, patients will be evaluated for eligibility to enroll into the study. Baseline visual acuity of the study subjects will be assessed with a 2.8X external telescope simulator (ETS) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts to determine if they are likely to benefit from receiving the IMT. To be included in the study and to proceed with the surgery, subjects must achieve, using the ETS, at least a one line (5 or more letters) improvement in distance on the ETDRS chart in the eye scheduled for surgery. Subjects not meeting these criteria will be excluded from the study. If eligible, they will be scheduled for out-patient surgery to implant the IMT during routine cataract surgery. Postoperatively, the surgeon will complete a usability and satisfaction questionnaire after each implantation procedure. The patients will undergo ophthalmic evaluations in both eyes at regular intervals for up to 12 months. The subjects will also be required to undergo 6 to 10 additional visits for vision training with a low vision specialist. Surgical complications, as well as all Adverse Event (AEs) and use of medications will be monitored from baseline to the end of the study.


Recruitment information / eligibility

Status Recruiting
Enrollment 76
Est. completion date December 2028
Est. primary completion date February 2027
Accepts healthy volunteers No
Gender All
Age group 55 Years and older
Eligibility Inclusion Criteria: 1. Be 55 years of age or older. 2. Have retinal findings of geographic atrophy or disciform scar with foveal involvement as determined by fluorescein angiography or OCT. 3. Have evidence of cataract. 4. Have best-corrected distance visual acuity (BCDVA) no better than 20/80 (0.6 LogMAR) and no worse than 20/800 (1.6 LogMAR) in both eyes. 5. Have adequate peripheral vision in the eye not scheduled for surgery, assessed by observation of ambulation. 6. Achieve at least a five-letter improvement on the ETDRS chart in the eye scheduled for surgery when using Samsara's 2.8X external telescope simulator (ETS, supplied separately). 7. Have an ACD of at least 2.5 mm in the eye scheduled for surgery. 8. Be willing to participate in a post-operative training program for the use of the NG SI IMT 3X implant. 9. Review and sign the Independent Ethics Committee (IEC)-approved Informed Consent Form (ICF) prior to any study-related procedures being performed. 10. Have adequate understanding of the local language to understand verbal and written subject information and be willing to comply with the study requirements. Exclusion Criteria: 1. Evidence of active choroidal neovascularization (CNV) on fluorescein angiography or OCT or were treated for CNV within the past six months. 2. Any ophthalmic pathology that compromises the patient's peripheral vision in the fellow eye. 3. A history of steroid-responsive rise in IOP, uncontrolled glaucoma, or preoperative IOP>22 mm Hg. 4. Corneal guttata. 5. Known sensitivity to post-operative medications. 6. Significant communication impairment or severe neurological disorders. 7. Have undergone previous intraocular or corneal surgery of any kind in the operative eye, including any type of surgery for either refractive or therapeutic purposes. 8. An ocular condition that predisposes the patient to eye rubbing. 9. Prior or expected ophthalmic-related surgery within 30 days preceding the NG SI IMT 3X implant surgery. 10. Patients for whom the planned operative eye has: - Myopia > 6.0 D - Hyperopia > 4.0 D - Axial length < 21 mm - Endothelial cell density < 1600 cells per square mm - Narrow angle, i.e., < Schaffer grade 2. 11. Inflammatory ocular disease. 12. Cornea stromal or endothelial dystrophies, including guttata. 13. Zonular weakness/instability of crystalline lens, or pseudoexfoliation. 14. Diabetic retinopathy. 15. Untreated retinal tears. 16. Retinal vascular disease. 17. Optic nerve disease. 18. A history of retinal detachment. 19. Retinitis pigmentosa. 20. Intraocular tumor. 21. Have received any investigational product within 30 days prior to study enrollment or be planning to participate in another investigation during the course of this study. 22. Be an employee (or a relative of an employee) of the contract research organization (CRO) responsible for conducting the study, Sponsor, or Sponsor representative. 23. Have a condition or be in a situation that, in the Investigator's opinion, may put the Subject at significant risk, may confound the study results, or may interfere significantly with the Subject's participation in the study.

Study Design


Intervention

Device:
SING IMT(TM) System, model NG SI IMT 3X
The SING IMT 3X implant is a visual prosthetic implantable device, which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with bilateral, end-stage age-related macular degeneration.

Locations

Country Name City State
Germany Augenklinik Städtisches Klinikum Karlsruhe Karlsruhe
Germany Universitätsklinikum Münster Klinik für Augenheilkunde Münster
Ireland Mater Misericordiae University Hospital Dublin
Italy Università degli Studi di Napoli Federico II Napoli
Italy Fondazione Policlinico Universitario Agostino Gemelli Roma
Spain VISSUM Alicante
Spain Institut OMIQ Barcelona
United Kingdom Royal Victoria Hospital Belfast Health & Social Care Trust Belfast

Sponsors (1)

Lead Sponsor Collaborator
VisionCare, Inc.

Countries where clinical trial is conducted

Germany,  Ireland,  Italy,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Device stability and fixation Assessed by slit lamp biomicroscopy examination: device tilt and device decentration 12 months
Other Post-operative anterior chamber depth (ACD) Anterior Chamber Depth (ACD) evaluated by ultrasound biomicroscopy (UBM), ocular coherence tomography (OCT) or another applicable test method 12 months
Primary Safety of the SING IMT System, model NG SI IMT 3X, including its delivery system The percent decrease in endothelial cell density (ECD). 12 months
Secondary Incision size needed for device implantation Incision size will not exceed 8.0 mm (non-inferiority assumption) in 75% of surgeries 12 moths
Secondary Surgical complications AEs and serious adverse events 12 moths
Secondary Improvement in near and distance best corrected visual acuity (BCVA) in implanted eyes. Near and distance BCVA will show an improvement of =2 lines in the ETDRS chart in at least 50% (non-inferior to 50%) of the implanted eyes at 12 months post implantation. 12 months
Secondary Usability of SING IMT System, including delivery system Surgeon will complete a usability and satisfaction questionnaire 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05984927 - NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration Phase 1/Phase 2
Active, not recruiting NCT05536297 - Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy Phase 3
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Completed NCT04005352 - Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) Phase 3
Withdrawn NCT02873351 - A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration Phase 2
Active, not recruiting NCT02802657 - Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration Phase 4
Not yet recruiting NCT02864472 - Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose Phase 4
Recruiting NCT01521065 - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Phase 2
Completed NCT02035722 - Intravitreal Injections-related Anxiety Phase 2/Phase 3
Completed NCT01445548 - Sirolimus for Advanced Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT01175395 - 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) Phase 1/Phase 2
Recruiting NCT01048476 - Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration Phase 1/Phase 2
Active, not recruiting NCT01174407 - Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration N/A
Terminated NCT00712491 - Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT00345176 - Age-Related Eye Disease Study 2 (AREDS2) Phase 3
Completed NCT02140151 - Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration Phase 1/Phase 2
Completed NCT02555306 - A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration Phase 1/Phase 2
Completed NCT03166202 - Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
Completed NCT01397409 - Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD) Phase 2
Recruiting NCT06174181 - Preventive TREatment of Dry Eye in Patients Receiving Repeated Intravitreal Injections for Age-related Macular Degeneration N/A